Kamada (NASDAQ:KMDA) Earns “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Kamada (NASDAQ:KMDA) in a research report sent to investors on Thursday morning,Benzinga reports. HC Wainwright currently has a $11.00 price objective on the biotechnology company’s stock. HC Wainwright also issued estimates for Kamada’s Q4 2024 earnings at $0.05 EPS, FY2025 earnings at $0.26 EPS, FY2026 earnings at $0.38 EPS, FY2027 earnings at $0.45 EPS and FY2028 earnings at $0.53 EPS.

Separately, StockNews.com lowered Kamada from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 27th.

Kamada Trading Down 0.9 %

Shares of NASDAQ KMDA opened at $5.81 on Thursday. The stock has a fifty day moving average price of $5.48 and a 200 day moving average price of $5.47. The company has a market cap of $333.96 million, a P/E ratio of 20.75 and a beta of 1.05. Kamada has a 12-month low of $4.60 and a 12-month high of $6.53.

Institutional Trading of Kamada

Several large investors have recently modified their holdings of the business. Public Employees Retirement System of Ohio purchased a new position in Kamada in the third quarter valued at about $77,000. Plato Investment Management Ltd purchased a new position in shares of Kamada during the 3rd quarter valued at approximately $117,000. Y.D. More Investments Ltd grew its position in shares of Kamada by 1,956.0% during the second quarter. Y.D. More Investments Ltd now owns 726,161 shares of the biotechnology company’s stock worth $3,643,000 after buying an additional 690,842 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in shares of Kamada by 8.2% in the first quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company’s stock worth $7,433,000 after buying an additional 100,800 shares during the last quarter. 20.38% of the stock is currently owned by institutional investors and hedge funds.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.